In contrast to the current data, Cybulski et al. [22], who tested the same 3 founder mutations in BRCA1, concluded that BRCA1 (5382insC) mutation is unlikely to be pathogenic for prostate cancer, but the increased risk was associated with the other two founder BRCA1 mutations (4153delA and C61G). Here, BRCA1 is linked to prostate carcinoma.